X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ASTRAZENECA PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ASTRAZENECA PHARMA CIPLA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 37.5 129.8 28.9% View Chart
P/BV x 3.9 19.7 19.6% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 CIPLA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
ASTRAZENECA PHARMA
Mar-14
CIPLA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6221,285 48.4%   
Low Rs458634 72.3%   
Sales per share (Unadj.) Rs181.9189.6 95.9%  
Earnings per share (Unadj.) Rs12.9-0.2 -6,321.3%  
Cash flow per share (Unadj.) Rs29.33.8 762.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs155.768.6 226.8%  
Shares outstanding (eoy) m804.5125.00 3,218.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.05.1 58.7%   
Avg P/E ratio x42.0-4,712.7 -0.9%  
P/CF ratio (eoy) x18.4249.6 7.4%  
Price / Book Value ratio x3.514.0 24.8%  
Dividend payout %15.50-   
Avg Mkt Cap Rs m434,51623,988 1,811.4%   
No. of employees `00023.01.6 1,478.1%   
Total wages/salary Rs m26,3381,605 1,641.4%   
Avg. sales/employee Rs Th6,349.13,040.2 208.8%   
Avg. wages/employee Rs Th1,143.01,029.2 111.1%   
Avg. net profit/employee Rs Th449.3-3.3 -13,762.8%   
INCOME DATA
Net Sales Rs m146,3024,740 3,086.7%  
Other income Rs m2,28792 2,483.1%   
Total revenues Rs m148,5894,832 3,075.2%   
Gross profit Rs m24,758-130 -19,073.9%  
Depreciation Rs m13,229101 13,072.4%   
Interest Rs m1,5940-   
Profit before tax Rs m12,222-139 -8,798.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m1,7985 35,316.3%   
Profit after tax Rs m10,354-5 -203,422.4%  
Gross profit margin %16.9-2.7 -617.9%  
Effective tax rate %14.7-3.7 -401.4%   
Net profit margin %7.1-0.1 -6,590.2%  
BALANCE SHEET DATA
Current assets Rs m87,3702,726 3,204.6%   
Current liabilities Rs m33,0812,435 1,358.6%   
Net working cap to sales %37.16.1 603.6%  
Current ratio x2.61.1 235.9%  
Inventory Days Days8774 117.9%  
Debtors Days Days6241 152.9%  
Net fixed assets Rs m111,5671,035 10,776.3%   
Share capital Rs m1,60950 3,218.0%   
"Free" reserves Rs m123,645942 13,120.2%   
Net worth Rs m125,2541,716 7,299.2%   
Long term debt Rs m36,4540-   
Total assets Rs m209,5324,156 5,041.7%  
Interest coverage x8.7NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.1 61.2%   
Return on assets %5.7-0.1 -4,655.9%  
Return on equity %8.3-0.3 -2,786.9%  
Return on capital %8.50-  
Exports to sales %34.25.7 600.1%   
Imports to sales %8.36.5 129.1%   
Exports (fob) Rs m50,050270 18,523.2%   
Imports (cif) Rs m12,203306 3,983.9%   
Fx inflow Rs m51,066375 13,632.2%   
Fx outflow Rs m17,678470 3,760.1%   
Net fx Rs m33,388-96 -34,943.3%   
CASH FLOW
From Operations Rs m23,824-8 -294,119.8%  
From Investments Rs m-13,127-146 9,009.3%  
From Financial Activity Rs m-13,239862 -1,535.4%  
Net Cashflow Rs m-2,478709 -349.8%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 0.3 4,066.7%  
FIIs % 23.7 15.7 151.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 9.1 287.9%  
Shareholders   161,166 12,856 1,253.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  DR. REDDYS LAB  GSK PHARMA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jun 21, 2018 (Close)

TRACK CIPLA

CIPLA - MERCK LTD COMPARISON

COMPARE CIPLA WITH

MARKET STATS